Christine Zedelmayer Sells 14,584 Shares of Equillium (NASDAQ:EQ) Stock

Posted by Stanley Muller on Jun 7th, 2026

Equillium, Inc. (NASDAQ:EQ – Get Free Report) COO Christine Zedelmayer sold 14,584 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $2.93, for a total transaction of $42,731.12. Following the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $183,376.98. This trade represents a 18.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The stock was sold at an average price of $2.80, for a total transaction of $240,833.60.
On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The stock was sold at an average price of $2.70, for a total transaction of $26,516.70.
On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total transaction of $300,780.00.
On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total transaction of $362,438.00.

Equillium Price Performance

Equillium stock opened at $2.94 on Friday. The firm has a market capitalization of $185.90 million, a PE ratio of -9.19 and a beta of 1.77. The company’s 50-day moving average is $2.20 and its 200-day moving average is $1.71. Equillium, Inc. has a fifty-two week low of $0.27 and a fifty-two week high of $3.45.

Equillium (NASDAQ:EQ – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). As a group, analysts expect that Equillium, Inc. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on EQ. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research report on Friday, March 27th. Leerink Partners raised shares of Equillium from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $1.00 to $6.00 in a report on Thursday, May 28th. Oppenheimer initiated coverage on shares of Equillium in a research note on Thursday, April 23rd. They issued an “outperform” rating and a $7.00 price objective for the company. Cantor Fitzgerald initiated coverage on shares of Equillium in a research note on Tuesday, April 7th. They set an “overweight” rating and a $10.00 price target for the company. Finally, Stifel Nicolaus set a $5.00 price target on shares of Equillium in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.57.

Get Our Latest Stock Analysis on EQ

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP bought a new position in shares of Equillium during the first quarter valued at about $31,000. Virtu Financial LLC increased its stake in shares of Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after purchasing an additional 13,591 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Equillium in the third quarter worth about $35,000. Persistent Asset Partners Ltd purchased a new position in shares of Equillium in the third quarter worth about $99,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Equillium in the first quarter worth about $100,000. 27.05% of the stock is currently owned by institutional investors and hedge funds.

Equillium Company Profile

(Get Free Report)

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.